422 related articles for article (PubMed ID: 19398072)
1. Kava Anxiety Depression Spectrum Study (KADSS): a mixed methods RCT using an aqueous extract of Piper methysticum.
Sarris J; Kavanagh DJ; Adams J; Bone K; Byrne G
Complement Ther Med; 2009 Jun; 17(3):176-8. PubMed ID: 19398072
[TBL] [Abstract][Full Text] [Related]
2. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward?
Sarris J; Teschke R; Stough C; Scholey A; Schweitzer I
Planta Med; 2011 Jan; 77(2):107-10. PubMed ID: 20814850
[TBL] [Abstract][Full Text] [Related]
3. The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum.
Sarris J; Kavanagh DJ; Byrne G; Bone KM; Adams J; Deed G
Psychopharmacology (Berl); 2009 Aug; 205(3):399-407. PubMed ID: 19430766
[TBL] [Abstract][Full Text] [Related]
4. St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial.
Sarris J; Kavanagh DJ; Deed G; Bone KM
Hum Psychopharmacol; 2009 Jan; 24(1):41-8. PubMed ID: 19090505
[TBL] [Abstract][Full Text] [Related]
5. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.
Sarris J; Stough C; Bousman CA; Wahid ZT; Murray G; Teschke R; Savage KM; Dowell A; Ng C; Schweitzer I
J Clin Psychopharmacol; 2013 Oct; 33(5):643-8. PubMed ID: 23635869
[TBL] [Abstract][Full Text] [Related]
6. Kava treatment in patients with anxiety.
Geier FP; Konstantinowicz T
Phytother Res; 2004 Apr; 18(4):297-300. PubMed ID: 15162364
[TBL] [Abstract][Full Text] [Related]
7. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study.
Sarris J; Scholey A; Schweitzer I; Bousman C; Laporte E; Ng C; Murray G; Stough C
Hum Psychopharmacol; 2012 May; 27(3):262-9. PubMed ID: 22311378
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines.
Malsch U; Kieser M
Psychopharmacology (Berl); 2001 Sep; 157(3):277-83. PubMed ID: 11605083
[TBL] [Abstract][Full Text] [Related]
9. Kava: a comprehensive review of efficacy, safety, and psychopharmacology.
Sarris J; LaPorte E; Schweitzer I
Aust N Z J Psychiatry; 2011 Jan; 45(1):27-35. PubMed ID: 21073405
[TBL] [Abstract][Full Text] [Related]
10. Kava-kava extract WS 1490 versus placebo in anxiety disorders--a randomized placebo-controlled 25-week outpatient trial.
Volz HP; Kieser M
Pharmacopsychiatry; 1997 Jan; 30(1):1-5. PubMed ID: 9065962
[TBL] [Abstract][Full Text] [Related]
11. Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial.
Savage KM; Stough CK; Byrne GJ; Scholey A; Bousman C; Murphy J; Macdonald P; Suo C; Hughes M; Thomas S; Teschke R; Xing C; Sarris J
Trials; 2015 Nov; 16():493. PubMed ID: 26527536
[TBL] [Abstract][Full Text] [Related]
12. Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study.
Sarris J; Byrne GJ; Bousman CA; Cribb L; Savage KM; Holmes O; Murphy J; Macdonald P; Short A; Nazareth S; Jennings E; Thomas SR; Ogden E; Chamoli S; Scholey A; Stough C
Aust N Z J Psychiatry; 2020 Mar; 54(3):288-297. PubMed ID: 31813230
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders.
Witte S; Loew D; Gaus W
Phytother Res; 2005 Mar; 19(3):183-8. PubMed ID: 15934028
[TBL] [Abstract][Full Text] [Related]
14. Kava (Piper methysticum).
J Soc Integr Oncol; 2009; 7(4):170-2. PubMed ID: 19883532
[No Abstract] [Full Text] [Related]
15. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial.
Gastpar M; Klimm HD
Phytomedicine; 2003 Nov; 10(8):631-9. PubMed ID: 14692723
[TBL] [Abstract][Full Text] [Related]
16. Kava-kava extract in anxiety disorders: an outpatient observational study.
Scherer J
Adv Ther; 1998; 15(4):261-9. PubMed ID: 10186945
[TBL] [Abstract][Full Text] [Related]
17. [Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis. Double blind study with placebos over 4 weeks].
Kinzler E; Krömer J; Lehmann E
Arzneimittelforschung; 1991 Jun; 41(6):584-8. PubMed ID: 1930344
[TBL] [Abstract][Full Text] [Related]
18. Anxiolytic properties of Piper methysticum extract samples and fractions in the chick social-separation-stress procedure.
Feltenstein MW; Lambdin LC; Ganzera M; Ranjith H; Dharmaratne W; Nanayakkara NP; Khan IA; Sufka KJ
Phytother Res; 2003 Mar; 17(3):210-6. PubMed ID: 12672148
[TBL] [Abstract][Full Text] [Related]
19. Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop.
Thomsen M; Schmidt M
J Ethnopharmacol; 2021 Mar; 268():113582. PubMed ID: 33189846
[TBL] [Abstract][Full Text] [Related]
20. [Kava-kava preparations--alternative anxiolytics].
Nowakowska E; Ostrowicz A; Chodera A
Pol Merkur Lekarski; 1998 Mar; 4(21):179-180a. PubMed ID: 9640076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
